![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 4
Zeitschriftenartikel
Müller, Rüdiger B.; Schulze-Koops, Hendrik; Furst, Daniel E.; Cohen, Stanley B.; Kwok, Kenneth; Wang, Lisy; Killeen, Tim und Kempis, Johannes von
(2022):
Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel).
In: Clinical Rheumatology, Bd. 41, Nr. 4: S. 1045-1055
Tony, Hans-Peter; Krüger, Klaus; Cohen, Stanley B.; Schulze-Koops, Hendrik; Kivitz, Alan J.; Jeka, Slawomir; Vereckei, Edit; Cen, Liyi; Kring, Laura und Kollins, Dmitrij
(2019):
Brief Report: Safety and Immunogenicity of Rituximab Biosimilar GP 2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis.
In: Arthritis Care & Research, Bd. 71, Nr. 1: S. 88-94
Müller, Rüdiger; Schulze-Koops, Hendrik; Furst, Daniel E.; Cohen, Stanley B.; Kwok, Kenneth; Maniccia, Anna; Wang, Lisy; Akylbekova, Ermeg und Kempis, Johannes von
(2017):
Effect of a Step-up or Step-Down in Tofacitinib Dose on Efficacy and Safety in Long-Term Extension Studies.
In: Arthritis & Rheumatology, Bd. 69
Tony, Hans-Peter; Schulze-Koops, Hendrik; Krüger, Klaus; Cohen, Stanley B.; Kivitz, Alan J.; Jeka, Slawomir; Vereckei, Edit; Cen, Liyi und Kollins, Dmitrij
(2017):
Comparison of Switching from the Originator Rituximab to the Biosimilar Rituximab GP2013 or Re-Treatment with the Originator Rituximab in Patients with Active Rheumatoid Arthritis: Safety and Immunogenicity Results from a Multicenter, Randomized, Double-Blind Study.
In: Arthritis & Rheumatology, Bd. 69